Clinical trial
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
NCT00353301 · University of Colorado, Denver, Other · Completed
Key facts
| NCT number | NCT00353301 |
|---|---|
| Title | Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma |
| Official title | A Phase II Single Arm Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Tarceva™ (Erlotinib Hydrochloride) and Rapamune™ (Sirolimus) in the Treatment of Metastatic Renal Cell Carcinoma. |
| Lead sponsor | University of Colorado, Denver, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Erlotinib hydrochloride, Sirolimus |
| Enrollment | 25 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Jul 18, 2006 |
| Last update posted | Apr 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: